Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Astellas Reels in EU Nod for Xtandi Use in Earlier Setting
April 25, 2024
- Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
April 25, 2024
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
- Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
- Pfizer’s PARP Inhibitor Talzenna Now Available in Japan
April 24, 2024
- Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease
April 24, 2024
- Takeda Inks Collab with Japan Cancer Research Foundation
April 23, 2024
- Takeda, Astellas, SMBC Join Forces to Fill Vally of Death in Japan
April 23, 2024
- Astellas Challenges Negative District Court Decision in Myrbetriq Patent Row
April 23, 2024
- Healthcare Stakeholders Already Fret Smaller Coverage for LLPs
April 23, 2024
- Roche Diagnostics Files 2 Alzheimer’s Test Assays for β-Amyloid, Tau
April 22, 2024
- Subcutaneous Entyvio Wins US FDA Nod for Crohn’s Disease: Takeda
April 22, 2024
- Alecensa Nabs Adjuvant Nod for ALK-Positive Lung Cancer in US
April 22, 2024
- Chugai to Commercialize Alnylam’s RNAi Hypertension Drug in Japan
April 22, 2024
- Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
- Fujifilm Shoots for 700 Billion Yen in Bio-CDMO Sales by FY2030
April 18, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…